InvestorsHub Logo
Followers 832
Posts 119787
Boards Moderated 17
Alias Born 09/05/2002

Re: OKY post# 8453

Friday, 02/29/2008 5:34:23 PM

Friday, February 29, 2008 5:34:23 PM

Post# of 19309
>How is the price for ATryn set?<

In Europe, the price is set separately in each country by negotiation between Leo and the government authorities responsible for reimbursement. The safety of ATryn compared to plasma-derived AT allowed Leo to establish a premium price in the UK (#msg-24708726, #msg-24712198).

GTC’s cost of production, which is probably less than 15% of the ATryn selling price (and will be even less when sales ramp up), is a minor factor in price negotiations because all parties realize that companies need to recover the huge R&D investment to bring a new drug to market.

In the US, the pricing of ATryn has not yet been determined; if and when the FDA approves ATryn for HD, GTC and its US partner will have to negotiate pricing with the various third-party payers. However, I think it’s reasonable to assume that the US price of ATryn will be in the $10,000-20,000 range per treatment due to the high price of Xigris and the scarcity of plasma-derived AT.

The price of Xigris matters for pricing in the HD indication because, as a practical matter, GTC will not be able to charge different prices for the same dose of ATryn depending on the indication. Thus, GTC will price Atryn for the HD indication in a way that takes into account the market dynamics in DIC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.